Cancer Treatment Reviews

Papers
(The H4-Index of Cancer Treatment Reviews is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review228
Editorial Board220
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)208
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty203
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives152
De-escalating adjuvant therapies in older patients with lower risk estrogen receptor-positive breast cancer treated with breast-conserving surgery: A systematic review and meta-analysis132
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials126
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas120
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer111
Systemic therapy for older patients with early breast cancer108
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer99
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis92
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer85
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group80
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in78
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?77
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications75
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis75
Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis72
De-escalation strategies with targeted therapies in non-small cell lung cancer68
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma68
Editorial Board66
Emerging antibody-based therapies for the treatment of acute myeloid leukemia65
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.62
If it’s a target, it’s a pan-cancer target: Tissue is not the issue60
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features60
Optimizing care in early phase cancer trials: The role of palliative care59
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis58
Uncertainties and controversies in axillary management of patients with breast cancer58
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches58
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges54
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials53
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?53
Editorial Board50
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment49
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck48
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes47
Roadmap to cure multiple myeloma46
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC46
Editorial Board44
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations44
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review43
Extracellular vesicles and the “six Rs” in radiotherapy43
0.19710683822632